FOXA2 and endometrium neoplasm: Nonetheless, the dramatic loss of FOXA2 expression in the majority of endometrial cell lines strongly suggests that (a) mutation rates underestimate the significance of FOXA2 as an endometrial tumor suppressor, and (b) additional, i.e., epigenetic or other regulatory mechanisms may account for FOXA2 protein loss.